TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28637445
Drug: Standard local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard local practice treatment for posterior fossa tumours
Study: 28637738
Drug: Immune monitoring
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune monitoring and immune-stimulating therapies
Study: 28638328
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with intravenous infusion of propofol and maintenance with isoflurane for 3 hours
Study: 28639987
Drug: Unfractioned heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractioned heparin, GPIs, bivalirudin
Study: 28642315
Drug: Aclidinium bromide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium bromide, dosage and duration not available
Study: 28642620
Drug: Pomalidomide (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (1-4 mg days 1-14), bortezomib (1-1.3 mg/m2), low-dose dexamethasone (LoDEX)
Study: 28642620
Drug: Bortezomib (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (subcutaneous (SC) or intravenous (IV))
Study: 28642620
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (LoDEX)
Study: 28642820
Drug: Standard tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tyrosine kinase inhibitors (TKI)
Study: 28642891
Drug: VX15/2503 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX15/2503 (1, 3, 6, 10, or 20 mg/kg)
Study: 28643275
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of nitisinone
Study: 28643275
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing of nitisinone
Study: 28644367
Drug: Cholic acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cholic acid (10 to 15 mg·kg·day)
Study: 28645776
Drug: Gilteritinib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib (oral, once daily) at various doses (20 mg, 40 mg, 80 mg, 120 mg, 200 mg, 300 mg, or 450 mg)
Study: 28645776
Drug: Gilteritinib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib (oral, once daily) at various doses
Study: 28645776
Drug: Gilteritinib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib (oral, once daily)
Study: 28645937
Drug: Guideline-recommended treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatments for ST-elevation myocardial infarction
Study: 28645937
Drug: Defect-free rate
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defect-free rate of guideline-recommended treatments
Study: 28646344
Drug: Chemotherapy A+B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy A+B (after biomarker information)
Study: 28646344
Drug: Chemotherapy A
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy A alone (without biomarker information)
Study: 28646344
Drug: Switch in
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch in treatment preference (after biomarker information)
Study: 28647272
Drug: Withdrawal or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal or withholding of life-sustaining therapy (WWLST) discussions
Study: 28648122
Drug: Dacomitinib 45-mg
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45-mg oral dose
Study: 28652228
Drug: Immediate intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate intervention group (n=17) received education session, Fitbit Flex, and weekly telephone counselling.
Study: 28653250
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (initiated by 990 survivors with estrogen-receptor-positive cancers)
Study: 28653504
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) site (n=2,286)
Study: 28654207
Drug: Grape polyphenols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape polyphenols (resveratrol, grape seed extract, grape juice; 2125 mg total polyphenols)
Study: 28654347
Drug: PulmoBind, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PulmoBind, a ligand of the adrenomedullin receptor, used for molecular imaging of pulmonary circulation.
Study: 28654574
Drug: Capecitabine 1000
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m² twice daily and Celecoxib 200 mg twice daily, day 1 to day 14 on a 21-day cycle
Study: 28655452
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 1000 mg twice daily with prednisone (P) 5 mg twice daily after progression from standard-dose therapy.
Study: 28655452
Drug: Standard-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose therapy of Abiraterone acetate (AA) 1000 mg daily with prednisone (P) 5 mg twice daily.
Study: 28656110
Drug: 2G (760
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2G (760 mg of n-3 FA)
Study: 28656110
Drug: 3G (1140
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3G (1140 mg of n-3 FA)
Study: 28656468
Drug: Self-administered implementation
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered implementation intention group
Study: 28657941
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with pathologic complete response (pCR)
Study: 28657941
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with residual disease
Study: 28657941
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with pCR and residual disease
Study: 28660406
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release (ER) 6 mg/day, titrated between 1.5 and 12 mg/day based on clinical response and tolerability
Study: 28662033
Drug: Pazopanib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib + escalating doses of 131I
Study: 28662235
Drug: Pembrolizumab in
Normalized name: pembrolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab in combination with metronomic cyclophosphamide (50 mg cyclophosphamide twice daily, 200 mg pembrolizumab every 3 weeks)
Study: 28662684
Drug: Continuous high-intensity
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-intensity interval cycle ergometer exercises with short-acting insulin doses reduced by 25%, 50%, and 75%.
Study: 28664499
Drug: Romidepsin 9
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 9 mg/m²
Study: 28664499
Drug: Romidepsin 14
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 14 mg/m²
Study: 28664507
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (ET) in RS ≤ 11 patients
Study: 28664507
Drug: Chemotherapy (anthracycline-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (anthracycline-containing or anthracycline-free) in RS 12-25 patients
Study: 28664507
Drug: Chemotherapy (anthracycline-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (anthracycline-containing or anthracycline-free) in RS > 25 patients
Study: 28666990
Drug: Biological age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological age gene score based on 1254 genes related to aging
Study: 28667381
Drug: Prandial premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial premixed therapy (PPT) - insulin lispro mix 50/50 thrice daily with meals
Study: 28667381
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy (BBT) - glargine at bedtime plus mealtime insulin lispro
Study: 28667563
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (CON)
Study: 28667569
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/day for 104 weeks
Study: 28667887
Drug: Low Amplitude
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Amplitude Seizure Therapy (LAP-ST, 0.5-0.6A)
Study: 28668141
Drug: hs-cTn concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTn concentrations ≥ 14 ng/L
Study: 28668141
Drug: Common low-risk
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common low-risk cutoff of 14 ng/L
Study: 28668244
Drug: Sublingual allergen-specific
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergen-specific immunotherapy (SLIT) with Staloral 300 SR Der p and Der f 50/50% extract
Study: 28668244
Drug: Sublingual allergen-specific
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergen-specific immunotherapy (SLIT)
Study: 28669012
Drug: Lapatinib (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (2500 mg twice daily for two consecutive days per week)
Study: 28670237
Drug: Adalimumab (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (160 mg at week 0, 80 mg at week 2, 40 mg every other week thereafter)
Study: 28670355
Drug: Non-thermal laser
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-thermal laser therapy
Study: 28673311
Drug: DSS in
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSS in combination with a custom multi-pad electrode design
Study: 28674057
Drug: Teicoplanin loading
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin loading dose (LD) of 600 mg and maintenance dose (MD) of 400 mg for ECMO patients not receiving continuous renal replacement therapy (CRRT)
Study: 28674057
Drug: Teicoplanin loading
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin loading dose (LD) of 800 mg and maintenance dose (MD) of 600 mg for ECMO patients receiving CRRT
Study: 28674057
Drug: Teicoplanin loading
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin loading dose (LD) of 1,000 mg and maintenance dose (MD) of 800 mg for ECMO patients not receiving CRRT
Study: 28674057
Drug: Teicoplanin loading
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin loading dose (LD) of 1,200 mg and maintenance dose (MD) of 1,000 mg for ECMO patients receiving CRRT
Study: 28674140
Drug: BTT1023 (anti-VAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTT1023 (anti-VAP monoclonal antibody)
Study: 28674870
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (doses converted to haloperidol equivalents)
Study: 28674982
Drug: Traditional pharmaceuticals
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Traditional pharmaceuticals
Study: 28674982
Drug: Gene therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapies
Study: 28674982
Drug: Antisense therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisense therapies targeting familial forms of ALS
Study: 28675695
Drug: Integrated psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated psychological intervention (IPI) including cognitive behavioural therapy (CBT) and supportive counselling (SC) for 12 months
Study: 28676651
Drug: D-dimer testing
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer testing with a fixed threshold of 0.25 mg/L FEU
Study: 28676842
Drug: DBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBS plus optimal drug therapy (DBS+ODT)
Study: 28677510
Drug: Fibrate monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrate monotherapy
Study: 28677510
Drug: Daily drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily drug intake
Study: 28677510
Drug: Forgot to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forgot to take medication
Study: 28677510
Drug: Stopped medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopped medication when cholesterol normal
Study: 28678647
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5% gel, liquid cleanser, and moisturizer SPF 30
Study: 28678771
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D status (25(OH)D <50 nmol/l)
Study: 28678771
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D status (25(OH)D ≥75 nmol/l)
Study: 28678771
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D status (25(OH)D 50-74.9 nmol/l)
Study: 28679598
Drug: MP-Ld (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-Ld (12.5 mg/kg)
Study: 28679598
Drug: MP-Hd (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-Hd (17.5 mg/kg)
Study: 28679598
Drug: LD+DDCI (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD+DDCI (3.5 mg/kg)
Study: 28679598
Drug: LD-DDCI (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-DDCI (17.5 mg/kg)
Study: 28680916
Drug: Lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic acid (LA) 1,200 mg daily
Study: 28681650
Drug: E6011 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 100 mg
Study: 28681650
Drug: E6011 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 400 mg
Study: 28683732
Drug: Common treatment
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common treatment regimens for AIS
Study: 28683732
Drug: Different treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different treatment regimens for AIS
Study: 28684537
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg by mouth on days 1 to 21), bortezomib (1.0 mg/m2 IV or subcutaneous), dexamethasone
Study: 28685973
Drug: Exenatide BID
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide BID (10 μg)
Study: 28686124
Drug: Convection-enhanced delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convection-enhanced delivery (CED) with a radiolabeled antibody
Study: 28687231
Drug: Different controller
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different controller therapies
Study: 28687349
Drug: Lung cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer screening and tobacco cessation program; details on dosage and duration not available.
Study: 28687625
Drug: Ofatumumab (OFA)
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab (OFA) infusion at an accelerated regimen: 300 mg on week 1 day 1, 1,000 mg on week 1 day 3, 2,000 mg on week 2 day 1, followed by weekly infusions for 8 weeks and monthly for 4 months.
Study: 28687627
Drug: Sorafenib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib and capecitabine combination therapy
Study: 28688730
Drug: Medical Orders
Normalized name: Orderable Drug Form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Orders for Scope of Treatment (MOST) documentation
Study: 28689278
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tHcy assessment and Ut-A Doppler
Study: 28690586
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (radiotherapy and chemotherapy)
Study: 28691931
Drug: Topical gentamicin
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gentamicin (0.1% ointment applied 3 times daily for 2 weeks)
Study: 28691931
Drug: Intradermal gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal gentamicin (8 mg solution injected daily for 2 days)
Study: 28691931
Drug: Placebo (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (topical and intradermal)
Study: 28692407
Drug: No formal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No formal treatment (Narcotics Anonymous/Alcoholics Anonymous or halfway house)
Study: 28692407
Drug: No postdetoxification
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postdetoxification treatment
Study: 28692407
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of drug overdose
Study: 28694343
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers non-withdrawal during acute heart failure
Study: 28694343
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers non-withdrawal during acute heart failure (ADCHF only)
Study: 28694343
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers non-withdrawal
Study: 28694343
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers withdrawal
Study: 28696231
Drug: Nafithromycin 800
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nafithromycin 800 mg once daily for 3 days
Study: 28698106
Drug: Loss in
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss in knee extensor strength in women concurrent with symptomatic progression
Study: 28698106
Drug: Loss in
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss in knee flexor strength in women concurrent with symptomatic progression
Study: 28698106
Drug: Loss in
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss in knee extensor and flexor strength concurrent with radiographic progression
Study: 28698330
Drug: Biological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological therapy (specific biologic agent not mentioned)
Study: 28699641
Drug: Nilotinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (300 to 400 mg twice daily)
Study: 28699641
Drug: Nilotinib dose
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib dose escalation for lack of efficacy
Study: 28699641
Drug: Nilotinib dose
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib dose reduction due to adverse events
Study: 28699641
Drug: Nilotinib re-escalation
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib re-escalation after dose reduction
Study: 28700265
Drug: Quadrivalent influenza
Normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent influenza vaccine (IIV4)
Study: 28700265
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza vaccine (IIV3) containing B Victoria-lineage strain
Study: 28700265
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza vaccine (IIV3) containing B Yamagata-lineage strain
Study: 28700272
Drug: MiniMed 640G
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiniMed 640G insulin pump
Study: 28701316
Drug: hs-cTnI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnI with delta hs-cTnI (0 and 3 h) >5 ng/L
Study: 28701571
Drug: nab-Paclitaxel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-Paclitaxel (150 mg/m2 weekly for four cycles)
Study: 28702291
Drug: Neonatal pneumococcal
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal pneumococcal conjugate vaccine
Study: 28702844
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA and LMWH
Study: 28702844
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of LMWH
Study: 28702844
Drug: ASA medication
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA medication
Study: 28705182
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and paclitaxel with concurrent radiotherapy (41.4-45 and 50.4 Gy)
Study: 28705184
Drug: POC 1-h
Normalized name: Bis(POC)PMPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: POC 1-h 50 g GCT (≥7.2 mmol/L [129.6 mg/dL])
Study: 28705532
Drug: Galantamine-memantine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine-memantine combination